𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial

✍ Scribed by Th. Witthöft; B. Möller; K. H. Wiedmann; St. Mauss; R. Link; J. Lohmeyer; M. Lafrenz; C. M. Gelbmann; D. Hüppe; C. Niederau; U. Alshuth

Book ID
108886026
Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
178 KB
Volume
14
Category
Article
ISSN
1352-0504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of peginterferon alp
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C
✍ Richard Njouom; Michèle Tagni Sartre; Isabelle Timba; Eric Nerrienet; Patrice Tc 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract Data were examined from a day‐to‐day clinical practice in Yaounde, Cameroon to evaluate the efficacy and safety of peginterferon alfa‐2a and ribavirin in treatment‐naive Cameroonian patients with chronic hepatitis C. Ninety adults with chronic hepatitis C (mean age, 53 ± 8 years; 79% ma

Efficacy and safety of peginterferon alf
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis
✍ Savino Bruno; Mitchell L. Shiffman; Stuart K. Roberts; Edward J. Gane; Diethelm 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 500 KB 👁 1 views

The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis